Vikas Lifecare Q3 FY26: Loss Widens Sharply Amid Revenue Decline

Vikas Lifecare Ltd reported a consolidated net loss of ₹29.28 Crores for the quarter ended December 31, 2025. Total consolidated revenue declined by 16.54% year-on-year to ₹97.76 Crores.

What Happened in Q3 FY26

Vikas Lifecare Ltd disclosed its financial results for the quarter and nine months ended December 31, 2025.

The company posted a standalone net loss of ₹14.72 Crores on standalone revenue of ₹96.39 Crores, which was down 13.50% year-on-year.

On a consolidated basis, the net loss widened significantly to ₹29.28 Crores from ₹6.86 Crores in the same quarter last year. Consolidated total income fell 16.54% to ₹97.76 Crores.

Significant losses from associate companies contributed ₹14.78 Crores to the consolidated deficit.

The company also noted the completion of the transfer of 51% equity shares in Ebix International Holdings Limited as part of an arbitration settlement.

Why It Matters

The widening losses alongside shrinking revenues indicate a challenging operational period for Vikas Lifecare.

Mounting debt levels and related party transactions conducted without shareholder consent raise governance and financial risk concerns.

Company Background

Vikas Lifecare operates a diversified business model, spanning pharmaceuticals, Fast-Moving Consumer Goods (FMCG), and agricultural inputs.

Historically, the company has been involved in chemical trading and manufacturing, including pharmaceutical excipients and agrochemicals.

The firm has previously faced investor concerns regarding its debt burden and the necessity of obtaining shareholder approval for related party transactions.

What's Next for Shareholders

Shareholders are now facing deteriorating financial performance, marked by declining revenues and escalating losses.

The company's increased borrowings require active debt management to prevent further financial strain and interest cost escalation.

Vikas Lifecare faces increased scrutiny on its corporate governance practices, particularly regarding obtaining prior shareholder consent for material related party deals.

Key Risks

Continued revenue contraction and the persistent widening of net losses.

The upward trajectory of consolidated borrowings, increasing financial leverage.

Potential regulatory or exchange repercussions for transacting material related party deals without requisite shareholder approvals.

The impact of associate company performance on overall consolidated results.

Peer Performance

Peers like Lasa Supergenics operate in related pharmaceutical segments. Lasa Supergenics reported a Q2 FY26 net profit of ₹12.5 crore on ₹114.6 crore revenue.

UPL Ltd, a major agrochemical firm, operates at a much larger scale, reporting Q3 FY24 profit of ₹1,199 crore on ₹14,959 crore revenue.

These comparisons highlight Vikas Lifecare's scale and current performance challenges relative to established players in its diverse business areas.

Key Financial Figures

Standalone revenue decreased year-on-year from ₹11,143.42 Lakhs in Q3 FY25 to ₹9,639.32 Lakhs in Q3 FY26.

Consolidated revenue declined from ₹11,712.49 Lakhs in Q3 FY25 to ₹9,775.81 Lakhs in Q3 FY26.

The consolidated quarterly net loss expanded to ₹29.28 Crores in Q3 FY26 from ₹6.86 Crores in Q3 FY25.

Consolidated borrowings increased from ₹37.70 Crores as of March 2025 to ₹68.82 Crores by September 2025.

What to Monitor

Management commentary on strategies to reverse the revenue decline and improve profitability.

Actions taken to address the escalating debt burden and manage financial leverage.

Steps for ensuring compliance with corporate governance norms, especially concerning shareholder approvals for related party transactions.

The financial performance of associate companies and their contribution to overall results.

Strategic implications and financial benefits arising from the Ebix International Holdings Limited stake transfer.